Bristol-Myers Squibb Expands Focus on Precision Medicine with Investment & Planned Collaboration with GRAIL on Blood-Based Ca...
March 01 2017 - 8:10AM
Business Wire
- Companies to enter a research
collaboration that utilizes GRAIL’s future analytics tools to
inform research, advance diagnostics and improve patient
outcomes
Bristol-Myers Squibb Company (NYSE: BMY) announced today its
equity investment and plans for a research collaboration with GRAIL
Inc., a life sciences company whose mission is to detect cancer
early when it potentially can be cured. By combining the power of
high intensity cancer DNA sequencing, leading edge computer science
and large clinical studies into a diagnostic platform, GRAIL aims
to develop highly sensitive blood tests that detect cancer in its
early stages to enable earlier intervention with targeted
therapies.
As an investor, Bristol-Myers Squibb will gain early access to
GRAIL’s comprehensive clinical trial databases that may serve as a
rich resource for understanding tumor genomics. Additionally,
Bristol-Myers Squibb and GRAIL have agreed to principal terms of a
research collaboration that would enable Bristol-Myers Squibb to
examine its clinical data using GRAIL’s analytic tools to inform
research and development decisions, guide strategies to advance
point of care companion diagnostics and potentially improve
selection, care and management of patients through more targeted
treatments.
“A key enabler of our Immuno-Oncology strategy is to leverage
precision medicine to speed the selection of the most effective
combinations of therapies for patients,” said Francis Cuss, MB
BChir, FRCP, chief scientific officer, Bristol-Myers Squibb.
“GRAIL’s future innovation potential is significant. Liquid
biopsies hold the potential to support much earlier intervention
and better define individual patient characteristics that may
enhance treatment decisions.”
Bristol-Myers Squibb has a diverse early portfolio of
Immuno-Oncology mechanisms it’s evaluating across a broad range of
tumors and modalities, with 10 investigational I-O molecules in the
clinic and ongoing registrational trials in 14 tumor types.
About Bristol-Myers
Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, YouTube and Facebook.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are
based on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking
statement can be guaranteed. Among other risks, there can be
no guarantee that the clinical studies discussed in this release
will be successfully developed or approved for any of the uses
described in this release. Forward-looking statements in this
press release should be evaluated together with the many
uncertainties that affect Bristol-Myers Squibb's business,
particularly those identified in the cautionary factors discussion
in Bristol-Myers Squibb's Annual Report on Form 10-K for the year
ended December 31, 2016 in our Quarterly Reports on Form 10-Q and
our Current Reports on Form 8-K. Bristol-Myers Squibb
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170301005876/en/
Bristol-Myers SquibbMedia:Ken Dominski,
609-252-5251ken.dominski@bms.comorLisa McCormick Lavery,
609-252-7602lisa.mccormicklavery@bms.comorInvestors:Tim
Power, 609-252-7509timothy.power@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024